Overview

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

Status:
Completed
Trial end date:
2010-08-04
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
Phase:
Phase 2
Details
Lead Sponsor:
Shire
Treatments:
Antidepressive Agents
Lisdexamfetamine Dimesylate